bempegaldesleukin,Nivolumab
Nektar,BMS
['nivo', 'sunitinib', 'rcc,(-irccs),(-srcc),(-urcc)', 'biomarker', 'marker ']
pegylated il-2 +nivo not beating sunitinib in 1st line advanced rcc. cr=2%, rr=23% (modest).primary progression rates 15% higher than sunitinib! pfsnot shown (unusual) il-2 chapter closes. the pdl1 biomarker data +ve. drug development stalled - it s time for biomarkers #esmo22 
Interested in Urology Cancers, biomarkers and drug development.